LTZ Therapeutics is an immunotherapy-focused biotech company
Location: United States
Employees: 11-50
Total raised: $85M
Investors 1
| Date | Name | Website |
| 17.01.2024 | Qiming Ven... | qimingvc.c... |
Funding Rounds 4
| Date | Series | Amount | Investors |
| 07.05.2026 | - | $38M | - |
| 30.07.2024 | Series A | $20M | - |
| 06.06.2023 | - | $10M | Shunwei Ca... |
| 08.04.2022 | Series A | $17M | - |
Mentions in press and media 11
| Date | Title | Description |
| 07.05.2026 | LTZ Therapeutics Raises $38M to Advance Immunotherapy Pipeline | Expansion of the U-MCE Immunotherapy Platform LTZ Therapeutics just raised $38 million to push forward its work on myeloid cell engagement therapies, bringing its total funding since launch to around $130 million. With this new cash, the co... |
| 07.05.2026 | LTZ Therapeutics Raises $38M in Funding | LTZ Therapeutics, a Redwood City, CA- and Shenzhen, China-based clinical-stage, immunotherapy-focused biotechnology company, raised $38M in funding. The round was led by GL Ventures, with participation from a sovereign wealth fund and exist... |
| 07.05.2026 | LTZ Therapeutics: $38 Million Financing Raised To Advance Myeloid Engager Immunotherapy Pipeline | LTZ Therapeutics announced the completion of an oversubscribed $38 million financing round to accelerate development of its Universal Myeloid Cell Engager immunotherapy platform and pipeline. The financing round was led by GL Ventures with ... |
| 31.07.2024 | Deals in brief: Beep closes USD 3.3 million round, M-DAQ Global acquires Easy Pay Transfers, ten China and India deals, and more | Beep closes USD 3.3 million pre-Series A round Beep, a Singapore-based internet-of-things company, has raised USD 3.3 million in a pre-Series A funding round led by Granite Asia, Farquhar VC, SUTD Venture Holdings, and Wing Vasiksiri, with ... |
| 30.07.2024 | LTZ Therapeutics Raises Over $20M in Series A Financing | LTZ Therapeutics, a Redwood City, CA- and Shenzen, China-based immunotherapy-focused biotech company, closed its Series A financing of over $20m. This round, which brought total funding to approximately $50m, was led by new investor Lapam C... |
| 30.07.2024 | LTZ Therapeutics Completes $20M+ Series A | REDWOOD CITY, CA, LTZ Therapeutics, an immunotherapy-focused biotech company, today announced the completion of the company's Series A financing of over $20 million. >> Click here for more funding data on LTZ Therapeutics >> To... |
| 06.06.2023 | LTZ Announces over $10 Million Pre-A+ Financing led by Qiming Venture Partners | - |
| 31.05.2023 | LTZ Therapeutics Raises Over $10M in Pre-A+ Financing | LTZ Therapeutics, a Redwood City, CA- and Shenzen, China-based immunotherapy-focused biotech company, raised over $10m in pre-A+ financing. The round was led by Qiming Venture Partners, with participation from Shunwei Capital, Lihehongxin V... |
| 08.04.2022 | LTZ Therapeutics Raises $17M in Pre-Series A Financing | LTZ Therapeutics, a Palo Alto, CA and Shenzhen, China-based biotech company, raised $17M in Pre-Series A funding. The round was led by K2 Venture Partners, with participation from Qiming Venture Partners and Tigermed. The company intends to... |
| - | LTZ Therapeutics | “LTZ Therapeutics ” |
Show more